- Home
- EYEN vs PSNL Comparison
EYEN vs PSNL Comparison
Compare EYEN & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- PSNL
- Stock Information
- Founded
- EYEN 2014
- PSNL 2011
- Country
- EYEN United States
- PSNL United States
- Employees
- EYEN N/A
- PSNL N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- EYEN Health Care
- PSNL Health Care
- Exchange
- EYEN Nasdaq
- PSNL Nasdaq
- Market Cap
- EYEN 2.9M
- PSNL 576.8M
- IPO Year
- EYEN 2018
- PSNL 2019
- Fundamental
- Price
- EYEN N/A
- PSNL $7.32
- Analyst Decision
- EYEN Hold
- PSNL Strong Buy
- Analyst Count
- EYEN 4
- PSNL 5
- Target Price
- EYEN $2.00
- PSNL $8.00
- AVG Volume (30 Days)
- EYEN 9.4M
- PSNL 1.7M
- Earning Date
- EYEN 08-11-2025
- PSNL 08-06-2025
- Dividend Yield
- EYEN N/A
- PSNL N/A
- EPS Growth
- EYEN N/A
- PSNL N/A
- EPS
- EYEN N/A
- PSNL N/A
- Revenue
- EYEN $67,063.00
- PSNL $85,694,000.00
- Revenue This Year
- EYEN $7,680.45
- PSNL $0.45
- Revenue Next Year
- EYEN $315.38
- PSNL $25.75
- P/E Ratio
- EYEN N/A
- PSNL N/A
- Revenue Growth
- EYEN 663.82
- PSNL 15.57
- 52 Week Low
- EYEN $0.85
- PSNL $1.19
- 52 Week High
- EYEN $124.80
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- EYEN 71.65
- PSNL 77.17
- Support Level
- EYEN $7.50
- PSNL $6.27
- Resistance Level
- EYEN $17.18
- PSNL $7.03
- Average True Range (ATR)
- EYEN 3.10
- PSNL 0.52
- MACD
- EYEN 0.88
- PSNL 0.08
- Stochastic Oscillator
- EYEN 81.29
- PSNL 83.65
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.